BiBBInstruments (BIBB) Q1 2025 earnings summary

Executive summary

• Strong start to 2025 with successful rights issue raising SEK 27.6 million and entry of a new strategic investor, Life Science Invest Fund 1 ApS.

• First commercial order for EndoDrill® GI from a US university hospital, marking the start of commercialization.

• EndoDrill® GI introduced at new hospitals in Europe and the US, with successful clinical demonstrations and positive multicenter study data confirming safety and efficacy.

• Focus ahead on scaling up Swedish production and signing distribution agreements for broader commercialization.

Financial highlights

• Net sales for Q1 2025 amounted to SEK 39 thousand, up from SEK 0 thousand in Q1 2024.

• Operating result for the quarter was SEK -2,862 thousand, compared to SEK -2,973 thousand in Q1 2024.

• Result after financial items was SEK -2,887 thousand (Q1 2024: SEK -2,971 thousand).

• Earnings per share were SEK -0.08 (Q1 2024: SEK -0.11).

• Cash and cash equivalents at March 31, 2025, were SEK 19,435 thousand (Q1 2024: SEK 5,657 thousand).

• Equity ratio improved to 95.5% (Q1 2024: 89.4%).

Outlook and guidance

• Priority on establishing volume manufacturing in Sweden and securing distribution partnerships for expanded commercialization.

• Plans for soft launch of EndoDrill® GI in autumn 2025, followed by broader launch in 2026.

• Next product, EndoDrill® EBUS for lung cancer diagnostics, targeted for launch in 2026.